Education
About Us
Working with TipRanks
Follow Us
Vertex Pharmaceuticals (VRTX)
NASDAQ:VRTX
VRTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$377.85 - $519.88
Previous CloseN/A
Volume295.43K
Average Volume (3M)1.61M
Market Cap
$124.48B
Enterprise Value$100.53B
Total Cash (Recent Filing)$396.55M
Total Debt (Recent Filing)$125.32M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
May 05, 2025EPS Estimate
4.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.20
Shares Outstanding257,080,840
10 Day Avg. Volume2,152,042
30 Day Avg. Volume1,610,429
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)11.73
Price to Cash Flow (P/CF)55.30
P/FCF Ratio54.90
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.59
Enterprise Value/Ebitda206.73
Forecast
1Y Price Target
$499.23Price Target Upside0.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering27
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceJournavx's contribution to the revised price objective has increased, reflecting its potential impact on financial performance.
Pipeline DevelopmentProgress for zimislecel continues with a pivotal trial underway, potentially leading to regulatory submission in 2026.
Product LaunchScripts available from the first four weeks of Journavx's launch continue to track well, showing strong initial demand.
Bears Say
Clinical TrialsVertex announced plans to discontinue its VX-264 program in T1D due to lack of efficacy, impacting investor sentiment negatively.
Product LimitationsThe required use of immunosuppressants with zimislecel could limit its uptake compared to expectations for VX-264.
Regulatory ChallengesThe majority of practices have yet to implement an official formulary coverage policy, which could take an average of 21 weeks to finalize.
---
Ownership Overview
0.21% Insiders
36.84% Mutual Funds
30.60% Other Institutional Investors
7.52% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VRTX FAQ
What was Vertex Pharmaceuticals’s price range in the past 12 months?
Vertex Pharmaceuticals lowest stock price was $377.85 and its highest was $519.88 in the past 12 months.
What is Vertex Pharmaceuticals’s market cap?
Vertex Pharmaceuticals’s market cap is $124.48B.
When is Vertex Pharmaceuticals’s upcoming earnings report date?
Vertex Pharmaceuticals’s upcoming earnings report date is May 05, 2025 which is in 20 days.
How were Vertex Pharmaceuticals’s earnings last quarter?
Vertex Pharmaceuticals released its earnings results on Feb 10, 2025. The company reported $3.98 earnings per share for the quarter, missing the consensus estimate of $4.016 by -$0.036.
Is Vertex Pharmaceuticals overvalued?
According to Wall Street analysts Vertex Pharmaceuticals’s price is currently Undervalued.
Does Vertex Pharmaceuticals pay dividends?
Vertex Pharmaceuticals does not currently pay dividends.
What is Vertex Pharmaceuticals’s EPS estimate?
Vertex Pharmaceuticals’s EPS estimate is 4.27.
How many shares outstanding does Vertex Pharmaceuticals have?
Vertex Pharmaceuticals has 257,080,840 shares outstanding.
What happened to Vertex Pharmaceuticals’s price movement after its last earnings report?
Vertex Pharmaceuticals reported an EPS of $3.98 in its last earnings report, missing expectations of $4.016. Following the earnings report the stock price went down -3.138%.
Which hedge fund is a major shareholder of Vertex Pharmaceuticals?
Currently, no hedge funds are holding shares in VRTX
---
Vertex Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$499.23 (0.69% Upside)
$499.23 (0.69% Upside)
Blogger Sentiment
Bullish
VRTX Sentiment 96%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 230.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.98%
12-Months-Change
Fundamentals
Return on Equity
-3.15%
Trailing 12-Months
Asset Growth
0.02%
Trailing 12-Months
Company Description
Vertex Pharmaceuticals
Vertex Pharmaceuticals (VRTX) is a global biotechnology company headquartered in Boston, Massachusetts. The company is primarily focused on the discovery, development, and commercialization of transformative medicines for serious diseases, with a strong emphasis on cystic fibrosis (CF). Vertex has developed several approved and marketed therapies to treat the underlying cause of CF, which have greatly improved the quality of life for patients with this genetic disease. The company's innovative approach is rooted in small molecule drug discovery and development, targeting diseases where there is a significant unmet need for effective treatment options.
---
VRTX Company Deck
---
VRTX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and successful product launches, signaling a positive momentum for Vertex's commercial and R&D efforts. However, the call also acknowledged challenges such as IP violations in Russia and increased operating expenses affecting profitability.Read More>---
VRTX Revenue Breakdown
60.66% U.S.
39.34% Europe
---
VRTX Stock 12 Month Forecast
Average Price Target
$499.23
▲(0.69% Upside)
Technical Analysis
Best Analysts Covering VRTX
1 Year
1 Year Success Rate
14/16 ratings generated profit
1 Year Average Return
+21.66%
reiterated a buy rating 2 months ago
Copying Olivia Brayer's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +21.66% per trade.
---